Disclosure Of Drug Costs By Manufacturers To Be Explored In FTC Hearings
Executive Summary
Drug companies' disclosure of Rx costs will be considered by the Federal Trade Commission in a series of hearings set to begin in February
You may also be interested in...
Health Plans’ Response To Claritin OTC Needs Monitoring For Collusion – WLF
The Washington Legal Foundation will be monitoring formulary decisions by managed care organizations for evidence of collusion following approval of OTC Claritin
Health Plans’ Response To Claritin OTC Needs Monitoring For Collusion – WLF
The Washington Legal Foundation will be monitoring formulary decisions by managed care organizations for evidence of collusion following approval of OTC Claritin
Waxman/Hatch Reinterpretation Underpins Change In 30-Month Stay Policy
FDA's proposal to allow only one 30-month stay of approval for ANDAs hinges on a reinterpretation of Waxman/Hatch language declaring that patent holders must be notified if a generic application is amended to "include" a Paragraph IV certification